MSM Protein Seizes Russian Antibody Opportunity
This article was originally published in Start Up
Executive Summary
Benefiting from pharma's ongoing love affair with antibodies-illustrated most recently in Bristol-Myers Squibb's $2 billion purchase of Medarex--Boston-based start-up MSM Protein Technologies signed two drug discovery deals in late July.
You may also be interested in...
Heptares Therapeutics Ltd.
Heptares Therapeutics has a technology that stabilizes GPCRs when they are removed from the cell membrane--overcoming one of the field's traditional challenges and allowing scientists to more easily study the receptors' structure and how ligands attach to and detach from them. Heptares' trick: introducing point mutations into GPCR genes that make them less flexible and likely to deform when removed from the cell wall. Heptares is going after small-molecule and antibody drugs in CNS and metabolic diseases.
4-antibody AG
4-antibody AG aims to produce fully-human, "gold standard" antibodies using its unique combination of tested technologies. The trump card: it reckons it can skirt the IP blackout zone created by pioneers around well-validated targets, thereby opening up an alterrnative route into existing, billion-dollar antibody markets.
Radiopharmaceuticals: A New Frontier In Precision Cancer Therapy
Growing interest in radioligand-based cancer therapies reflects the class’s unique advantages – including the ability to “see what you treat.”